Kim Byung Sup, Kong Doo-Sik, Seol Ho Jun, Nam Do-Hyun, Lee Jung-Il
Department of Neurosurgery, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Republic of Korea.
Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
J Clin Neurosci. 2017 Jan;35:35-41. doi: 10.1016/j.jocn.2016.10.002. Epub 2016 Oct 18.
Residual or recurrent hemangiopericytoma (HPC) has been treated with radiosurgery; however, its long-term outcome is not well known. This study is to investigate the long-term outcome of gamma knife radiosurgery (GKS) for residual or recurrent HPCs. We conducted a retrospective analysis of 18 patients who underwent gamma knife radiosurgery for residual or recurrent HPCs. Of the 18 patients, 10 patients had high-grade HPCs (27 tumors) and 8 had low-grade HPCs (13 tumors). Median overall survival (OS) after the first GKS was 134.7months and actuarial survival rate at 1, 5, and 10years was 85.6%, 85.6%, and 37.4%, respectively. At the last follow-up, local tumor control was achieved in 32 (80.0%) of the 40 GKS-treated tumors. New lesions developed out of initial GKS target in 8 patients (44.4%). They were also treated with additional GKS. The actuarial local control rate of 40 tumors at 1-, 3-, and 5-years was 89.3%, 60.9%, and 37.5%, respectively. The median local recurrence-free interval of 40 tumors after initial GKS for each lesion was 86.1months for low-grade and 40.5months for high-grade tumors (p=0.010). Extracranial metastases developed in 7 (38.9%) patients with high-grade pathology and became a cause of death in 3 patients. Intracranial tumor control can be achieved over the long term, though additional GKS is frequently necessary. Extracranial metastasis is common in HPC of high-grade pathology. Close surveillance and aggressive treatment is recommended not only for intracranial tumor but also for possible extracranial metastases.
残留或复发性血管外皮细胞瘤(HPC)已采用放射外科治疗;然而,其长期疗效尚不清楚。本研究旨在探讨伽玛刀放射外科(GKS)治疗残留或复发性HPC的长期疗效。我们对18例接受伽玛刀放射外科治疗残留或复发性HPC的患者进行了回顾性分析。18例患者中,10例为高级别HPC(27个肿瘤),8例为低级别HPC(13个肿瘤)。首次GKS后的中位总生存期(OS)为134.7个月,1年、5年和10年的精算生存率分别为85.6%、85.6%和37.4%。在最后一次随访时,40个接受GKS治疗的肿瘤中有32个(80.0%)实现了局部肿瘤控制。8例患者(44.4%)在初始GKS靶区外出现了新病灶,这些患者也接受了额外的GKS治疗。40个肿瘤1年、3年和5年的精算局部控制率分别为89.3%、60.9%和37.5%。每个病灶初始GKS后,40个肿瘤的低级别和高级别肿瘤的中位局部无复发生存期分别为86.1个月和40.5个月(p=0.010)。7例(38.9%)高级别病理患者发生颅外转移,其中3例因颅外转移死亡。虽然经常需要额外的GKS,但长期来看颅内肿瘤控制是可以实现的。颅外转移在高级别病理的HPC中很常见。建议不仅对颅内肿瘤,而且对可能的颅外转移进行密切监测和积极治疗。